Pledpharma: Aladote upside

Research Update



Redeye reiterates its base case valuation of SEK 15 following the Q1 2020 report. Due to the negative news about PledOx this year, our valuation solely rests on Aladote, where we do see a credible pathway forward, and we expect a pivotal Phase 2/3 trial can be initiated about year-end.


Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.